104 related articles for article (PubMed ID: 16330570)
1. Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotide.
Verwijnen SM; Krenning EP; Valkema R; Huijmans JG; de Jong M
J Nucl Med; 2005 Dec; 46(12):2057-60. PubMed ID: 16330570
[TBL] [Abstract][Full Text] [Related]
2. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.
de Jong M; Rolleman EJ; Bernard BF; Visser TJ; Bakker WH; Breeman WA; Krenning EP
J Nucl Med; 1996 Aug; 37(8):1388-92. PubMed ID: 8708781
[TBL] [Abstract][Full Text] [Related]
4. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.
Rolleman EJ; Valkema R; de Jong M; Kooij PP; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):9-15. PubMed ID: 12483404
[TBL] [Abstract][Full Text] [Related]
5. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.
van Eerd JE; Vegt E; Wetzels JF; Russel FG; Masereeuw R; Corstens FH; Oyen WJ; Boerman OC
J Nucl Med; 2006 Mar; 47(3):528-33. PubMed ID: 16513623
[TBL] [Abstract][Full Text] [Related]
6. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose.
Rolleman EJ; Krenning EP; Van Gameren A; Bernard BF; De Jong M
J Nucl Med; 2004 Apr; 45(4):709-13. PubMed ID: 15073269
[TBL] [Abstract][Full Text] [Related]
7. Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.
Melis M; de Swart J; de Visser M; Berndsen SC; Koelewijn S; Valkema R; Boerman OC; Krenning EP; de Jong M
J Nucl Med; 2010 Dec; 51(12):1962-8. PubMed ID: 21078795
[TBL] [Abstract][Full Text] [Related]
8. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.
de Jong M; Barone R; Krenning E; Bernard B; Melis M; Visser T; Gekle M; Willnow TE; Walrand S; Jamar F; Pauwels S
J Nucl Med; 2005 Oct; 46(10):1696-700. PubMed ID: 16204720
[TBL] [Abstract][Full Text] [Related]
9. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
12. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences.
Melis M; Krenning EP; Bernard BF; de Visser M; Rolleman E; de Jong M
Nucl Med Biol; 2007 Aug; 34(6):633-41. PubMed ID: 17707803
[TBL] [Abstract][Full Text] [Related]
13. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues.
Melis M; Krenning EP; Bernard BF; Barone R; Visser TJ; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1136-43. PubMed ID: 15912401
[TBL] [Abstract][Full Text] [Related]
14. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
Jamar F; Barone R; Mathieu I; Walrand S; Labar D; Carlier P; de Camps J; Schran H; Chen T; Smith MC; Bouterfa H; Valkema R; Krenning EP; Kvols LK; Pauwels S
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):510-8. PubMed ID: 12582815
[TBL] [Abstract][Full Text] [Related]
15. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.
Breeman WA; De Jong MT; De Blois E; Bernard BF; De Jong M; Krenning EP
Nucl Med Biol; 2004 Aug; 31(6):821-4. PubMed ID: 15246375
[TBL] [Abstract][Full Text] [Related]
16. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes.
Duncan JR; Stephenson MT; Wu HP; Anderson CJ
Cancer Res; 1997 Feb; 57(4):659-71. PubMed ID: 9044843
[TBL] [Abstract][Full Text] [Related]
17. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
Anderson CJ; Pajeau TS; Edwards WB; Sherman EL; Rogers BE; Welch MJ
J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
[TBL] [Abstract][Full Text] [Related]
20. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H
Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
